MedTrace Logo

Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation

NCT01024491 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2009-12-02

No results posted yet for this study

Summary

As study to investigate the efficacy and safety of daily doses of paroxetine of 15 and 20 mg for the treatment of premature ejaculation

Conditions

  • Premature Ejaculation

Interventions

DRUG

paroxetine

daily dose of paroxetine 15mg for 12 weeks

DRUG

paroxetine

active daily treatment with paroxetine 20 mg

DRUG

placebo

active daily treatment with placebo

Sponsors & Collaborators

  • MorePharma Corporation

    lead INDUSTRY

Principal Investigators

  • Eusebio Rubio-Aurioles, M.D, Ph.D. · Asociacion Mexicana para la Salud Sexual, A.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024491 on ClinicalTrials.gov